PMID: 7475593Oct 14, 1995Paper

Breast and ovarian cancer incidence after infertility and in vitro fertilisation

Lancet
Alison VennDavid L Healy

Abstract

Concern has been expressed that exposure to fertility drugs might be associated with a risk of ovarian cancer. We have examined the incidence of breast and ovarian cancer in a cohort of 10,358 women referred for in-vitro fertilisation (IVF) treatment in Victoria, Australia, between 1978 and 1992. The "exposed" group (n = 5564) had had ovarian stimulation to induce multiple folliculogenesis and the "unexposed" group (n = 4794) had been referred for IVF but were untreated or had had "natural cycle" treatment without ovarian stimulation. Duration of follow-up ranged from 1 to 15 years. Cases of cancer were determined by record linkage with data from population-based cancer registries. 34 cases of invasive breast cancer and 6 of invasive ovarian cancer were observed. A comparison with the expected numbers, derived by applying age-standardised general population rates to the cohort gave standardised incidence ratios (SIR) for breast cancer of 0.89 (95% CI 0.55-1.46) in the exposed group and 0.98 (0.62-1.56) in the unexposed group, and for ovarian cancer SIRs were 1.70 (0.55-5.27) and 1.62 (0.52-5.02), respectively. Rates of all cancers were not significantly different from general population rates. The relative risk (RR) of cancer, ...Continue Reading

References

Sep 1, 1992·Obstetrical & Gynecological Survey·G W CreasyD Upmalis
Jul 29, 1989·BMJ : British Medical Journal·S Fishel, P Jackson
Jun 18, 1994·Lancet·D L HealyA N Andersen
Sep 22, 1994·The New England Journal of Medicine·M A RossingS G Self

❮ Previous
Next ❯

Citations

Nov 1, 1996·Journal of Assisted Reproduction and Genetics·R J Paulson
Apr 1, 1997·Journal of Assisted Reproduction and Genetics·R J Paulson
Sep 3, 2010·Breast Cancer Research and Treatment·Tony G ZreikBouthaina Dabaja
Mar 15, 2008·Cancer Causes & Control : CCC·Charlotte Gerd HannibalSusanne Krüger Kjaer
Jul 16, 2009·Current Treatment Options in Oncology·Thanasak Sueblinvong, Michael E Carney
Sep 1, 1996·Obstetrics and Gynecology·N P KoperA L Verbeek
Jul 1, 1996·European Journal of Obstetrics, Gynecology, and Reproductive Biology·O JourdainD Dallay
Sep 15, 2004·Fertility and Sterility·UNKNOWN Practice Committee of the American Society for Reproductive Medicine
Sep 15, 2004·Fertility and Sterility·UNKNOWN Practice Committee of the American Society for Reproductive Medicine
Feb 1, 2002·Fertility and Sterility·Jehoshua DorBaruch Modan
Nov 11, 2003·Fertility and Sterility·UNKNOWN Practice Committee of the American Society for Reproductive Medicine
Dec 12, 2003·Fertility and Sterility·Michael P SteinkampfKaren Hammond
Jun 1, 1997·Fertility and Sterility·B J MosgaardA N Andersen
Dec 16, 1998·Fertility and Sterility·B J MosgaardA N Andersen
Feb 5, 1999·Obstetrics and Gynecology·B S Houmard, D B Seifer
Jul 31, 1999·European Journal of Obstetrics, Gynecology, and Reproductive Biology·A ShushanJ G Schenker
Jun 5, 2002·Molecular and Cellular Endocrinology·Peter J FullerHenry G Burger
Jan 28, 1999·Molecular and Cellular Endocrinology·J S TapanainenI T Huhtaniemi
Jan 29, 1999·Endocrinology and Metabolism Clinics of North America·B J Vollenhoven, D L Healy
Mar 18, 1999·Hematology/oncology Clinics of North America·G Emons, J J Kavanagh
Aug 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MandaiT Mori
May 22, 2003·Best Practice & Research. Clinical Obstetrics & Gynaecology·Alison VennRobert McLachlan
Apr 21, 1999·Clinical Endocrinology·T RimanS Nilsson
Mar 22, 2002·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·R J Edmondson, J M Monaghan
Mar 13, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·L Lerner-GevaA Amit
Dec 14, 2004·The New England Journal of Medicine·Stephen A Cannistra
Nov 20, 2010·Human Reproduction·B KällénP Otterblad Olausson
Feb 22, 2012·Human Reproduction·A-N Yli-KuhaE Hemminki
Jul 26, 2013·Human Reproduction Update·Theodoros N SergentanisEleni Th Petridou
Sep 2, 1999·Journal of the National Cancer Institute·R B Ness, C Cottreau
Jul 10, 2012·Journal of the National Cancer Institute·Chunyuan FeiClarice R Weinberg
Jun 17, 2005·Biology of Reproduction·William J Murdoch
Jun 10, 1998·Current Opinion in Obstetrics & Gynecology·K Duckitt, A A Templeton
Feb 7, 2001·Current Opinion in Obstetrics & Gynecology·K E Wakeley, E C Grendys
Jan 26, 1999·Clinical Obstetrics and Gynecology·C Schmidt-Sarosi
May 9, 2002·Obstetrical & Gynecological Survey·Abraham Benshushan, Amnon Brzezinski
May 16, 2009·Cancer Nursing·Monica R McLemoreMarylin J Dodd
May 2, 2001·The Journal of Obstetrics and Gynaecology Research·V Sivanesaratnam
Jul 1, 1998·British Journal of Obstetrics and Gynaecology·D NugentA J Rutherford
Feb 7, 2009·BMJ : British Medical Journal·Allan JensenSusanne Krüger Kjaer
Jul 16, 2005·Gynecologic and Obstetric Investigation·Ismail OzdemirFuat Demirci

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Incidence & Mortality

Cancer has emerged as a global concern due to its increase in incidence and mortality. Efforts are underway to evaluate and develop action plans to reduce the global burden of cancer. Currently, lung cancer, breast cancer and prostate cancer are the leading causes of cancer mortality. Here is the latest research on cancer incidence and mortality.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.